{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-027644","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2023-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.192439+00:00","generated_at":"2026-06-14T02:00:49.683556+00:00","sec_items":["5.02","5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Ultragenyx annual meeting approves 2023 Incentive Plan and A&R ESPP; three directors re-elected","bullets":["Stockholders elected Class I directors Emil Kakkis (58.8M for), Shehnaaz Suliman (55.7M for), Daniel Welch (52.3M for).","2023 Incentive Plan approved: 42.0M for, 18.0M against; 5.0M broker non-votes.","A&R ESPP approved with 59.7M for, 262,515 against.","Ernst & Young ratified as independent auditor for FY2023 (63.99M for, 934,903 against).","Advisory say-on-pay passed with 56.7M for, 3.2M against."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-027644","json":"https://secwatch.observer/filing/0000950170-23-027644.json","markdown":"https://secwatch.observer/filing/0000950170-23-027644.md","text":"https://secwatch.observer/filing/0000950170-23-027644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023027644/0000950170-23-027644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023027644/rare-20230607.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T02:00:49.683556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1301db32c23819b4beb591c0947f0fec9c9f1a33","claim":"Ultragenyx Pharmaceutical Inc. shareholders approved Approval of the A&R ESPP at the 2023-06-07 meeting.","evidence_excerpt":"Proposal No. 3 – Approval of the A&R ESPP At the Annual Meeting, the Company’s stockholders approved the A&R ESPP. The votes on Proposal 3 were as follows: Votes For Votes Against Abstentions Broker Non-Votes 59,717,345 262,515 5,566 5,026,508","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023027644/0000950170-23-027644-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-07"}],"fact_type":"shareholder_vote"},{"claim_id":"13357ef6acda9804685d6ea6e3dc4adc3135a1c8","claim":"Ultragenyx Pharmaceutical Inc. shareholders approved Election of Class I Directors at the 2023-06-07 meeting.","evidence_excerpt":"Proposal No. 1 – Election of Class I Directors At the Annual Meeting, the Company’s stockholders elected the Class I director nominees below to the Company’s Board of Directors to hold office until the 2026 Annual Meeting of Stockholders or until their successors are elected. The votes on Proposal 1 were as follows: Class I Director Nominees Votes For Votes Withheld Broker Non-Votes Emil D. Kakkis, M.D., Ph.D. 58,836,682 1,148,744 5,026,508 Shehnaaz Suliman, M.D. 55,707,622 4,277,804 5,026,508 Daniel G. Welch 52,266,359 7,719,067 5,026,508","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023027644/0000950170-23-027644-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-07"}],"fact_type":"shareholder_vote"},{"claim_id":"40333bc8b01d7890c3b66c9763eafbab65cec241","claim":"Ultragenyx Pharmaceutical Inc. shareholders approved Approval of the 2023 Plan at the 2023-06-07 meeting.","evidence_excerpt":"Proposal No. 2 – Approval of the 2023 Plan At the Annual Meeting, the Company’s stockholders approved the 2023 Plan. The votes on Proposal 2 were as follows: Votes For Votes Against Abstentions Broker Non-Votes 41,971,776 18,008,590 5,060 5,026,508","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023027644/0000950170-23-027644-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-07"}],"fact_type":"shareholder_vote"},{"claim_id":"5682e575206ddabd70b8b8dc75cfef620c30e7e7","claim":"Ultragenyx Pharmaceutical Inc. shareholders approved Advisory Vote to Approve Executive Compensation at the 2023-06-07 meeting.","evidence_excerpt":"Proposal No. 5 – Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company’s stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its “named executive officers” as described in the Proxy Statement. The votes on Proposal 5 were as follows: Votes For Votes Against Abstentions Broker Non-Votes 56,684,278 3,204,523 96,625 5,026,508","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023027644/0000950170-23-027644-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-07"}],"fact_type":"shareholder_vote"},{"claim_id":"6a4e4929dad99034c6deaf3f4c22adcbabcbca52","claim":"Ultragenyx Pharmaceutical Inc. shareholders approved Ratification of Selection of Independent Registered Accounting Firm at the 2023-06-07 meeting.","evidence_excerpt":"Proposal No. 4 – Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. The votes on Proposal 4 were as follows: Votes For Votes Against Abstentions 63,986,340 934,903 90,691","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023027644/0000950170-23-027644-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-07"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}